Cargando…

Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma

AIMS: Primary mediastinal large B-cell lymphoma (PMBL) diagnosis can be challenging on needle biopsies. Robust techniques are needed to ensure diagnosis of this lymphoma which is highly sensitive to recently developed therapy protocols. METHODS: In this study, we sought to determine precise PMBL phe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacquier, Anthony, Syrykh, Charlotte, Bedgedjian, Isabelle, Monnien, Franck, Laurent, Camille, Valmary-Degano, Séverine, Brousset, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142454/
https://www.ncbi.nlm.nih.gov/pubmed/32839159
http://dx.doi.org/10.1136/jclinpath-2020-206747
_version_ 1783696555350425600
author Jacquier, Anthony
Syrykh, Charlotte
Bedgedjian, Isabelle
Monnien, Franck
Laurent, Camille
Valmary-Degano, Séverine
Brousset, Pierre
author_facet Jacquier, Anthony
Syrykh, Charlotte
Bedgedjian, Isabelle
Monnien, Franck
Laurent, Camille
Valmary-Degano, Séverine
Brousset, Pierre
author_sort Jacquier, Anthony
collection PubMed
description AIMS: Primary mediastinal large B-cell lymphoma (PMBL) diagnosis can be challenging on needle biopsies. Robust techniques are needed to ensure diagnosis of this lymphoma which is highly sensitive to recently developed therapy protocols. METHODS: In this study, we sought to determine precise PMBL phenotype, compared with diffuse large B-cell lymphoma not otherwise specified, by combining immunohistochemistry with anti-MAL antibody and RNA in situ hybridisation (RNAscope) with specific MAL probes. RESULTS: The overall MAL positivity level reached 93% (14/15) of cases of PMBL. Among the 15 cases enrolled in the study, 11 were undoubtedly positive for MAL immunostaining whereas 13 were positive by RNA in situ hybridisation. Interestingly, one case that was negative by in situ hybridisation turned out to be positive by immunohistochemistry. CONCLUSIONS: Taken together, our results demonstrate that in situ detection of both MAL transcripts and protein are complementary and increase the sensitivity and specificity of PMBL diagnosis.
format Online
Article
Text
id pubmed-8142454
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-81424542021-06-07 Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma Jacquier, Anthony Syrykh, Charlotte Bedgedjian, Isabelle Monnien, Franck Laurent, Camille Valmary-Degano, Séverine Brousset, Pierre J Clin Pathol Short Report AIMS: Primary mediastinal large B-cell lymphoma (PMBL) diagnosis can be challenging on needle biopsies. Robust techniques are needed to ensure diagnosis of this lymphoma which is highly sensitive to recently developed therapy protocols. METHODS: In this study, we sought to determine precise PMBL phenotype, compared with diffuse large B-cell lymphoma not otherwise specified, by combining immunohistochemistry with anti-MAL antibody and RNA in situ hybridisation (RNAscope) with specific MAL probes. RESULTS: The overall MAL positivity level reached 93% (14/15) of cases of PMBL. Among the 15 cases enrolled in the study, 11 were undoubtedly positive for MAL immunostaining whereas 13 were positive by RNA in situ hybridisation. Interestingly, one case that was negative by in situ hybridisation turned out to be positive by immunohistochemistry. CONCLUSIONS: Taken together, our results demonstrate that in situ detection of both MAL transcripts and protein are complementary and increase the sensitivity and specificity of PMBL diagnosis. BMJ Publishing Group 2021-06 2020-08-24 /pmc/articles/PMC8142454/ /pubmed/32839159 http://dx.doi.org/10.1136/jclinpath-2020-206747 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Short Report
Jacquier, Anthony
Syrykh, Charlotte
Bedgedjian, Isabelle
Monnien, Franck
Laurent, Camille
Valmary-Degano, Séverine
Brousset, Pierre
Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma
title Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma
title_full Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma
title_fullStr Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma
title_full_unstemmed Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma
title_short Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma
title_sort immunohistochemistry with anti-mal antibody and rnascope with mal probes are complementary techniques for diagnosis of primary mediastinal large b-cell lymphoma
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142454/
https://www.ncbi.nlm.nih.gov/pubmed/32839159
http://dx.doi.org/10.1136/jclinpath-2020-206747
work_keys_str_mv AT jacquieranthony immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma
AT syrykhcharlotte immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma
AT bedgedjianisabelle immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma
AT monnienfranck immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma
AT laurentcamille immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma
AT valmarydeganoseverine immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma
AT broussetpierre immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma